Sweden has made recent advancements in cancer blood tests & AI
The latest major advancement in breast cancer testing and screening in Sweden is the implementation of AI-supported breast cancer screening developed through Lund University's MASAI trial, alongside new liquid biopsy blood tests for recurrence monitoring
Screening for Non-Specific Symptoms: A study involving Karolinska Institutet evaluated plasma protein profiling in patients presenting with vague symptoms like fatigue or weight loss at Swedish hospitals to help triage high-risk patients faster for imaging like PET-CT.
Early Biomarkers for Multiple Cancers: Researchers at Uppsala University identified specific combinations of protein and metabolite biomarkers in 2026 that can detect ovarian, lung, and colorectal cancers in blood samples with performance levels matching or exceeding those of traditional methods.
Low-DNA Detection Method (BayesCNA): Scientists at Chalmers University of Technology and the University of Gothenburg developed a new analysis method in mid-2026 that can reliably track tumor progression and DNA composition from blood samples containing as little as 5% cancer DNA (down from the 15–20% previously required)
The Stockholm3 test from Karolinska Institutet for more accurate, earlier detection of aggressive prostate cancer, alongside new research on multi-cancer and protein biomarkers.
